The holy grail: pan-cancer-targeting T cells

Crowther and Dolton et al. identified an unconventional human T cell clone capable of killing many different types of cancer in vitro in an HLA-independent fashion while sparing healthy cells. Using genome-wide CRISPR-Cas9 screening, the researchers showed that the T cell clone recognized the ubiquitously expressed, mostly monomorphic, MHC-I-related protein MR1 on the surface of cancer cells when MR1 was loaded with a yet unidentified cancer-specific or cancer-associated ligand. Adoptive transfer of this T cell clone into immunodeficient NSG mice with leukemia reduced tumor burden and increased survival.

Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer

Advances in Targeting CAR-T Therapy for Immune-Mediated Diseases

Michael G King Jr (@MichaelGKingJr) / X

Frontiers Targeting KRAS mutations in pancreatic cancer

Targeting KRAS in pancreatic adenocarcinoma: Progress in

Biomedicines, Free Full-Text

Frontiers Progress Toward Identifying Exact Proxies for

Role of nanotechnology and gene delivery systems in TRAIL based

Biology, Free Full-Text

Detection and localization of early- and late-stage cancers using

Drugging KRAS: current perspectives and state-of-art review

CIMT Annual Meeting 2022

Novel strategies for cancer immunotherapy: counter-immunoediting

Pan-cancer T cell atlas links a cellular stress response state to